Valuation: Vericel Corporation

Market Cap 2.05B 1.83B 1.71B 1.55B 2.93B 199B 2.94B 20.53B 8.04B 101B 7.71B 7.54B 325B P/E 2026 *
72.6x
P/E 2027 * 45.6x
Enterprise Value 2.05B 1.83B 1.71B 1.55B 2.93B 199B 2.94B 20.53B 8.04B 101B 7.71B 7.54B 325B EV / Sales 2026 *
6.11x
EV / Sales 2027 * 5.23x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -
1 day+0.12%
1 week-0.12%
Current month-0.10%
1 month+2.85%
3 months-16.99%
6 months+19.38%
Current year+11.36%
1 week 39.5
Extreme 39.5
41.45
1 month 37.35
Extreme 37.35
41.45
Current year 28.95
Extreme 28.95
49.32
1 year 28.95
Extreme 28.95
49.32
3 years 28.95
Extreme 28.95
63
5 years 17.3
Extreme 17.3
63
10 years 2
Extreme 2
68.94
Manager TitleAgeSince
Chief Executive Officer 62 2013-02-28
Director of Finance/CFO 51 2021-01-24
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 71 2005-09-27
Chairman 75 2012-10-04
Director/Board Member 57 2013-08-22
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/26 Exercice

Director

21,000 0.0411%
8/3/26 Exercice

Chief Operating Officer

30,000 0.0587%
7/30/26 Exercice

Controller/Auditor

13,500 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%-0.12%+22.37%+16.71% 2.05B
+0.83%+3.19%+37.87%+106.25% 1,051B
+1.93%+2.11%+36.82%+64.90% 630B
+1.49%+5.19%+19.84%+85.41% 489B
+2.26%+0.90%+66.40%+39.33% 359B
+1.45%+3.50%+21.87%+42.64% 344B
+1.17%+2.37%+11.71%+35.14% 272B
+0.89%+1.08%-7.28%+10.52% 246B
+1.82%+2.94%+40.43%+52.78% 224B
+2.77%+4.44%+29.49%+101.40% 187B
Average +1.36%+2.26%+27.95%+55.51% 380.58B
Weighted average by Cap. +1.20%+2.44%+31.56%+69.94%

Financials

2026 *2027 *
Net sales 336M 300M 279M 254M 480M 32.54B 482M 3.36B 1.32B 16.59B 1.26B 1.23B 53.24B 393M 351M 326M 297M 561M 38.03B 563M 3.93B 1.54B 19.39B 1.48B 1.44B 62.21B
Net income 29.29M 26.16M 24.33M 22.13M 41.79M 2.83B 41.97M 293M 115M 1.45B 110M 108M 4.64B 47.29M 42.23M 39.29M 35.74M 67.47M 4.58B 67.76M 473M 185M 2.33B 178M 174M 7.49B
Net Debt - -
Projected Income Statement - Annual - Vericel Corporation
Logo Vericel Corporation
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Employees
398
Date Price Change Volume
26-10-09 US$40.10 +0.12% 506,885
26-10-08 US$40.05 -1.69% 749,140
26-10-07 US$40.74 +1.72% 647,001
26-10-06 US$40.05 -2.48% 669,043
26-10-05 US$41.07 +2.29% 648,584
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Vericel Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
40.10USD
Average target price
60.57USD
Spread / Average Target
+51.05%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Vericel Corporation
  1. Stock Market
  2. Stocks
  3. VCEL Stock